Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 222, Issue 1, Pages 38-43Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa228
Keywords
Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survival rate; Viral shedding
Categories
Funding
- National Natural Science Foundation of China [81970517]
- Zhongyuan (Henan) Thousands Outstanding Talents Plan [ZYQR201912179]
- Foundation for Distinguished Young Talents of Zhengzhou University Medical School [2020ZQLMS]
- Key Scientific Research Project of Henan Higher Education Institutions of China [20B320028]
Ask authors/readers for more resources
Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available